We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation.
- Authors
Liu, K.-Y.; Chen, Y.-H.; Liu, D.-H.; Xu, L.-P.; Huang, X.-J.
- Abstract
The objective of this study was to determine the efficacy and safety of low-dose recombinant interleukin-2(IL-2) administered to patients with acute lymphoblastic malignancy at high-risk of relapse after unmanipulated HLA-identical or HLA-haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT). We studied 19 patients with acute lymphoblastic malignancy who underwent IL-2 treatment for a high probability of disease recurrence after allo-HSCT between July 2004 and June 2006 at Peking University Institute of Hematology. With a median follow-up of 6 months (range, 3–19 months) after the first IL-2 therapy, 14 of 15 evaluable patients in our cohort were disease-free (93.33%), whereas one patient in ‘high risk’ pretransplantation category relapsed. Toxicities from IL-2 were mainly fever, pain, redness and swelling at the injection site. Four patients left the study because of hyperpyrexia. Local and reversible chronic GVHD was observed in 6 of 15 patients (40%). Similar cGVHD occurrences were observed between the two groups of patients undergoing HLA-identical HSCT (three of seven patients) and HLA-haploidentical HSCT (two of six patients), respectively. In conclusion, low-dose IL-2 subcutaneous administration from 100 days for a prolonged period could be a safe and effective strategy to prevent relapse in acute lymphoblastic malignancy patients with high risk of recurrence after unmanipulated allo-HSCT.Bone Marrow Transplantation (2008) 42, 535–539; doi:10.1038/bmt.2008.208; published online 21 July 2008
- Subjects
INTERLEUKIN-2; LYMPHOBLASTIC leukemia; HEMATOPOIETIC stem cells; STEM cell transplantation; GRAFT versus host disease; T cells
- Publication
Bone Marrow Transplantation, 2008, Vol 42, Issue 8, p535
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2008.208